| Q33522351 | Acute toxicity of a single dose DATR, recombinant soluble human TRAIL mutant, in rodents and crab-eating macaques |
| Q39972640 | Adenoviral-mediated Rybp expression promotes tumor cell-specific apoptosis |
| Q57243583 | Apoptosis pathways: turned on their heads? |
| Q36017772 | Apoptosis-based therapies and drug targets |
| Q35684085 | Biologic premises of combined radiation therapy and chemotherapy in lung cancer |
| Q46090981 | Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells |
| Q44582774 | Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition |
| Q40081513 | DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells |
| Q40518043 | Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). |
| Q37390893 | Death receptors as targets for anti-cancer therapy |
| Q39455419 | Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies |
| Q36076428 | Down-modulation of heat shock protein 70 and up-modulation of Caspase-3 during schisandrin B-induced apoptosis in human hepatoma SMMC-7721 cells |
| Q40603990 | Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. |
| Q44125748 | Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver |
| Q40031192 | Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells |
| Q24798681 | Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis |
| Q35372514 | Isolation of a TRAIL antagonist from the serum of HIV-infected patients. |
| Q42278494 | Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. |
| Q50527664 | Preclinical toxicity of DATR, a recombinant soluble human TRAIL mutant, in rats and cynomolgus monkeys. |
| Q35177652 | Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences |
| Q39985088 | Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism |
| Q40533297 | Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). |
| Q60960591 | TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase |
| Q37462599 | TRAIL-deficient mice exhibit delayed regression of retinal neovascularization |
| Q28391040 | Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells |
| Q33208795 | Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies. |